Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention

被引:97
|
作者
Tong, Xin [1 ]
Pelling, Jill C.
机构
[1] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA
关键词
Akt; mTOR; apigenin; cancer; CELL-CYCLE ARREST; CHEMOPREVENTIVE BIOFLAVONOID APIGENIN; CYCLOOXYGENASE-2; COX-2; EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; GLUTATHIONE-S-TRANSFERASE; HUMAN PANCREATIC-CANCER; CYTOCHROME-C RELEASE; FLAVONOID APIGENIN; DIETARY FLAVONOIDS; TUMOR-CELLS;
D O I
10.2174/18715206113139990119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Natural products are important sources of anti-cancer lead molecules, and high dietary consumption of fruits and vegetables is associated with a reduced risk of certain cancers. Many efforts have been devoted to identifying and developing plant-derived dietary constituents as chemopreventive agents. Among them, apigenin, a naturally occurring flavonoid found in a variety of fruits and leafy vegetables, has been shown to possess remarkable anti-oxidant, anti-inflammatory and anti-carcinogenic properties. This review summarizes the anti-cancer and chemopreventive effects of apigenin at cellular and molecular levels, its chemical structure and properties, with focus on mechanism related to apigenin's inhibition of the PI3K/Akt/mTOR signaling pathways.
引用
收藏
页码:971 / 978
页数:8
相关论文
共 50 条
  • [31] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [32] Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook
    Cho, Daniel C.
    BIODRUGS, 2014, 28 (04) : 373 - 381
  • [33] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [34] Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
    LoPiccolo, Jaclyn
    Blumenthal, Gideon M.
    Bernstein, Wendy B.
    Dennis, Phillip A.
    DRUG RESISTANCE UPDATES, 2008, 11 (1-2) : 32 - 50
  • [35] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : 335 - 342
  • [36] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
  • [37] PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
    Zhu, Kunrui
    Wu, Yanqi
    He, Ping
    Fan, Yu
    Zhong, Xiaorong
    Zheng, Hong
    Luo, Ting
    CELLS, 2022, 11 (16)
  • [38] Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects
    Stanciu, Silviu
    Ionita-Radu, Florentina
    Stefani, Constantin
    Miricescu, Daniela
    Stanescu-Spinu, Iulia-Ioana
    Greabu, Maria
    Totan, Alexandra Ripszky
    Jinga, Mariana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [39] Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
    Barra, Fabio
    Evangelisti, Giulio
    Desideri, Lorenzo Ferro
    Di Domenico, Stefano
    Ferraioli, Domenico
    Vellone, Valerio Gaetano
    De Cian, Franco
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 131 - 142
  • [40] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
    Mabuchi, Seiji
    Kuroda, Hiromasa
    Takahashi, Ryoko
    Sasano, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179